化合物EN3356 T30161

Product Introduction
Bioactivity


英文名: EN3356

描述: EN3356 是一种可口服且具有选择性的类固醇 17-α- 羟化酶/C17,20 裂解酶（CYP17A1 或 CYP17）抑制剂，是一种非甾体类裂解酶选择性化合物，具有潜在的抗雄激素和抗肿瘤活性。

体内活性: EN3356 (50, 100, 200 mg; oral; escalating doses; once a day) was well tolerated, and drug-related AEs were CTCAE Gr 1 and 2 incl. myalgia, anorexia, flushing, hot flashes, and presyncope. Excellent systemic exposure was observed at both 50 mg and 100 mg QD regimens (Cmax, Ctrough, and AUCτ at 100 mg QD were 3.5 uM, 1.8 uM, and 52 uM.h, respectively). The Phase 1 clinical study results to date show that EN3356 is safe and well tolerated at doses of up to 100 mg daily.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 7.5 mg/mL (24.97 mM)


关键字: ASN 001 | EN-3356 | AS N-001 | AS N 001 | EN 3356 | EN3356 | ASN001

相关产品: Fenofibrate | Topiroxostat | 1-Aminobenzotriazole | Liarozole | Naringin | 8alpha-Tigloyloxyhirsutinolide 13-O-acetate | 2,3-dihydrothieno-Thiadiazole Carboxylate | Nampt activator-2 | MCH-1 antagonist 1 | 7-Ethoxyresorufin

相关库: Drug Repurposing Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | Bioactive Compound Library

化合物EN3356 T30161信息由TargetMol中国为您提供，如您想了解更多关于化合物EN3356 T30161报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途